Zomedica Corp. (ZOM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZOM POWR Grades
- ZOM scores best on the Growth dimension, with a Growth rank ahead of 67.08% of US stocks.
- ZOM's strongest trending metric is Sentiment; it's been moving down over the last 35 weeks.
- ZOM ranks lowest in Stability; there it ranks in the 1st percentile.
ZOM Stock Summary
- With a price/sales ratio of 17,710.48, Zomedica Corp has a higher such ratio than 99.78% of stocks in our set.
- ZOM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.38% of US stocks.
- In terms of volatility of its share price, ZOM is more volatile than 99.01% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Zomedica Corp, a group of peers worth examining would be URG, CVM, TFFP, CALT, and MRSN.
- Visit ZOM's SEC page to see the company's official filings. To visit the company's web site, go to www.zomedica.com.
ZOM Valuation Summary
- ZOM's EV/EBIT ratio is -19.6; this is 166.89% lower than that of the median Healthcare stock.
- ZOM's price/sales ratio has moved NA NA over the prior 46 months.
- ZOM's price/sales ratio has moved NA NA over the prior 46 months.
Below are key valuation metrics over time for ZOM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZOM | 2021-08-31 | 20836.7 | 2.3 | -34.9 | -19.6 |
| ZOM | 2021-08-30 | 20216.7 | 2.2 | -33.9 | -18.5 |
| ZOM | 2021-08-27 | 20640.0 | 2.2 | -34.6 | -19.2 |
| ZOM | 2021-08-26 | 22533.3 | 2.4 | -37.8 | -22.4 |
| ZOM | 2021-08-25 | 18940.0 | 2.1 | -31.7 | -16.4 |
| ZOM | 2021-08-24 | 16623.3 | 1.8 | -27.9 | -12.5 |
ZOM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZOM has a Quality Grade of F, ranking ahead of 3.99% of graded US stocks.
- ZOM's asset turnover comes in at 0 -- ranking 438th of 677 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ZOM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | -0.393 | -5.936 |
| 2021-03-31 | 0 | 0.599 | -5.609 |
| 2020-12-31 | 0 | NA | -5.395 |
| 2020-09-30 | 0 | NA | -6.260 |
| 2020-06-30 | 0 | NA | -6.329 |
| 2020-03-31 | 0 | NA | -5.504 |
ZOM Stock Price Chart Interactive Chart >
ZOM Price/Volume Stats
| Current price | $0.52 | 52-week high | $2.91 |
| Prev. close | $0.54 | 52-week low | $0.06 |
| Day low | $0.51 | Volume | 56,105,600 |
| Day high | $0.55 | Avg. volume | 86,147,148 |
| 50-day MA | $0.59 | Dividend yield | N/A |
| 200-day MA | $0.98 | Market Cap | 513.57M |
Zomedica Corp. (ZOM) Company Bio
Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.
Latest ZOM News From Around the Web
Below are the latest news stories about Zomedica Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.
Sean Whelan Appointed to Board of DirectorsANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vacancy created by the resignation of Christopher Wolfenberg. Robert Cohen, Zomedica’s Chief Executive Officer, commented that: “We all are very pleased to be joined by an executive with Sean’s sterling ba |
If at First Zomedica Doesn’t Succeed, It Tries, Tries AgainThe launch of the Truforma diagnostic platform didn't go perfectly for Zomedica, but holders of ZOM stock still have reason for optimism. |
Zomedica Continues to Execute PoorlyIt's been 3.5 months since Zomedica launched Truforma. |
Zomedica’s Business Model Is Good, But It’s Still OverpricedGiving away razors and charging for the blades is often a good idea, but ZOM stock still isn't a good value until it drops closer to 40 cents. |
Thinking about buying stock in Sonnet BioTherapeutics, Vinco Ventures, Regional Health Properties, Zomedica, or Support.com?NEW YORK , Aug. 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, BBIG, RHE, ZOM, and SPRT. |
ZOM Price Returns
| 1-mo | 10.17% |
| 3-mo | -36.47% |
| 6-mo | -66.01% |
| 1-year | 642.86% |
| 3-year | -74.63% |
| 5-year | N/A |
| YTD | 125.50% |
| 2020 | -30.33% |
| 2019 | -73.09% |
| 2018 | -37.88% |
| 2017 | 91.99% |
| 2016 | N/A |
Loading social stream, please wait...